Responses
Extended essay
A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 4 July 2017
- Published on: 4 July 2017Masters and Nutt draw attention to deficiencies in Emanuel, Wendler, and Grady 2000.
In their intriguing 'Plutocratic Proposal' (J Med Ethics 2017), Masters and Nutt note that the 'Matching Agencies' acting as intermediaries between benefactors and the beneficiaries would need to do systematic reviews of all known existing research and commit to publishing full research results, both for their own reputations and for legal protection . Masters and Nutt point out out that these are definitely ethical matters, and that failure to do one or both has had fatal consequences for patients and research participants.
How can it be that Emanuel, Wendler and Grady did not even mention these two vital points concerning publication in their original list of seven ethical requirements? (JAMA 2000:283:701-7011).
Conflict of Interest:
None declared.
Other content recommended for you
- Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer
- Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
- Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
- Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
- Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma
- CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
- Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
- Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers
- Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
- Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy